We previously developed an MHC class II‐restricted multi‐peptide vaccine (EVax) that targets both mouse and human wildtype EGFR.[11] EVax is thus designed to enhance EGFR protein‐specific CD4+ T cell activation and recruit anti‐tumor effector immune cells to tumor sites. Here, CD4 is linked to neoplasm.